Business

Know the Business — How Anthem Actually Makes Money, and What That's Worth

Anthem is a fee-for-service CRDMO that rents integrated chemistry, biology and FDA-graded reactor capacity to global drug innovators, and runs a higher-margin specialty-ingredients book on the same fermentation plant. Roughly 14 commercial molecules supply 60.8% of FY26 revenue, with a 200-program development pipeline feeding the next generation. The market is paying ~72× trailing earnings for the cleanest margin and capital-efficiency profile in the listed Indian CRDMO peer set — the debate is not whether the business is high quality, it is whether late-stage pipeline conversion holds the multiple intact when revenue is structurally lumpy.

1. How This Business Actually Works

Takeaway: Anthem sells two things from one set of plants — outsourced drug R&D-to-manufacturing for Western innovators (CRDMO, 83% of revenue, dollar-denominated, fee-for-service) and brand-like fermentation-based specialty APIs sold mostly into India and ROW (17%). The economic engine inside both is the same: build cGMP-grade reactor and fermentation capacity ahead of demand, win discovery work with small biotechs on a fee-for-deliverable basis, then graduate those molecules through phases 1-3 until a few commercial molecules supply most of the cash. Each commercial win turns into a 10-20 year supply annuity because tech-transfer is contractually onerous and FDA-graded.

The mechanics that actually drive incremental profit: fixed-cost plants (custom synthesis 425 kL, fermentation 142 kL across Units I-III), variable raw materials at ~38% of revenue, and labour that is semi-fixed. Once utilization crosses ~70% on a unit — which Units I and II have reached, per Q3 FY26 management — each new commercial molecule throws off 50%-plus EBITDA contribution. The CFO's commentary on FY26 margin improvement traces almost entirely to (a) eliminating Chinese intermediate sourcing (backward-integrated in-house), and (b) operating leverage from higher capacity loading, not pricing.

Two things separate Anthem from the median Indian CRDMO. First, the customer base is biotech-heavy (>550 of 675+ clients are emerging biotech in US/Europe/Japan) and billed FFS, not FTE — that means margin closer to a fabless chemical business, less close to a staffing firm. Second, the platform breadth is unusual for the size: peptides (16 kL commercial facility), RNAi delivery (glycolipid platform since 2016), ADC linkers (one in late-phase), fermentation oligonucleotides, biotransformation — and the fermentation plant supplies both CRDMO contracts and the specialty-ingredient brand book. The two segments are not separable for valuation because they share the asset base.

2. The Playing Field

Takeaway: Among six listed Indian CRDMOs, Anthem runs the highest operating margin and highest return on capital despite being the fourth-largest by revenue. The right comparator framing is not "Indian CDMO" — it is "fully integrated CRDMO with biotech-skewed FFS customer base," and the only peer that fully matches on both dimensions is Sai Life Sciences.

Anthem sits in the top-right corner alone — every other integrated CRDMO is either margin-weaker or capital-less-efficient at the same scale. Syngene is the legacy benchmark but is paying the price for an FTE-heavy customer book; its margin compressed from 29% to 25% in FY26 and ROCE has halved over five years as FY26 revenue grew only 3%. Sai Life Sciences is the cleanest functional twin — same FFS model, biotech-skewed, growing fast — but earns materially lower returns on capital. Divi's is the largest and earns comparable margins, but its book is much more API/generic-tilted with single-customer concentration in custom synthesis. Cohance and Piramal Pharma are not credible comparators on returns — Cohance's margins collapsed post-merger and Piramal Pharma loses money on a 10% operating margin.

The benchmark Anthem has to beat to justify its premium is its own past margin trajectory, not the peer median. EBITDA margins have run between 38% and 48% for five years; if FY26 Q4's 48% holds into FY27, the case is durable. If FY26's 43% reverts toward the FY24 trough of 38% as Unit-3 ramps absorb mix, the valuation thins.

Aragen Life Sciences — private, Goldman-backed, comparable scale, biologics-tilted — is the threat the listed peer set doesn't show. When Aragen lists (filings indicate 2026-27), the comparable set widens and the pricing of late-stage molecule books gets re-tested.

3. Is This Business Cyclical?

Takeaway: Not cyclical the way consumer or industrial businesses are. The cycle that hits Anthem is biotech funding, customer destocking, and clinical-trial attrition — and it shows up in revenue 12-18 months after the leading indicator turns. Margin is far less cyclical than topline because the customer mix is sticky.

The FY22-23 contraction (revenue from ₹1,231 cr to ₹1,057 cr) traces directly to the 2022 biotech funding crash — VC funding to discovery-stage biotech fell from $43.8B (CY21) to $23.5B (CY23) — combined with one large molecule's destocking. Note what didn't happen: margins stayed above 40%, and the commercial molecule revenue (~60% even then) cushioned the decline. The lesson: short-cycle exposure is real, but the durable commercial molecule book is the shock absorber.

The current cycle indicator to watch is destocking. Management called this out twice in FY26 — biotech and large-pharma customers reduced safety-stock days because of US-India trade tension and currency volatility, which is why 9M FY26 grew only 11-12% against management's own 20% guidance. By Q4 FY26 management said destocking is largely behind, RFQs have stepped up, and Q4 grew 26% YoY. If RFQ volume holds, the 20% growth aspiration for FY27 is plausible — if not, expect another lumpy year.

The longer-cycle threat is geopolitics, not biotech funding. The BIOSECURE Act, if passed, redirects Western outsourcing away from China; Anthem is named in independent industry reports as a likely beneficiary. The opposite tail — US-India trade escalation — was visible in FY26 and management explicitly cited it as the destocking trigger.

4. The Metrics That Actually Matter

Takeaway: P/E and R&D intensity are weak signals for this business. The five metrics that genuinely drive value and explain failure are commercial-molecule count, late-stage pipeline depth, capacity utilization, gross-fixed-asset turn, and EBITDA margin durability.

The non-obvious ones: commercial-molecule count is the single most useful operating KPI because each addition compounds for over a decade, and FY26 added four (vs one or two per year prior). Phase-3 count is the leading indicator for FY28-30 — six is a respectable book but smaller than Sai Life's 16. Customer concentration is the disclosure investors should press for; "5 of top 6 molecules to three customers" implies the top three may control upward of 40% of revenue. R&D intensity (1.1% of revenue) is deliberately low for a CRDMO — most R&D is customer-funded — and is not the warning sign it would be for an innovator pharma.

5. What Is This Business Worth?

Takeaway: Value here is determined by the molecule book — how many commercial molecules pay the rent today, how many late-stage ones convert into commercial in 2-5 years, and whether 40%+ EBITDA margin and 25%+ ROCE survive the Unit-4 capex cycle. The correct lens is forward P/E or EV/EBITDA on a multi-year FCF trajectory, anchored to disclosed commercial-molecule progression. Not SOTP — the two segments share the asset base.

Trailing P/E sits at ~72×, EV/EBITDA at ~43× (mkt cap ₹43,856 Cr less net cash ₹1,374 Cr = EV ₹42,482 Cr; FY26 EBITDA ₹990 Cr). On management's stated 20% PAT growth aspiration the FY27 P/E lands around 60×, and ~50× FY28. Sai Life trades at ~69× FY26 P/E on weaker capital efficiency (ROCE 19.6%); Divi's at 83×; Syngene at 59× on a deteriorating margin profile. Anthem's premium within that range is paid for the cleanest margin-ROCE combination, not for growth.

Sum-of-the-parts is not the right lens. Specialty ingredients shares the fermentation plant with the CRDMO segment, management is the same team, capital allocation is unified, and disclosed segment economics are not separable in any reliable way. Treat both segments as one engine valued on the molecule book and asset productivity. The discipline is to underwrite the next decade of commercial-molecule conversion, not to model two segments independently.

The cheap-or-expensive question reduces to three judgments: (1) does the commercial-molecule book compound from 14 to 25+ over the next five years; (2) does EBITDA margin hold north of 40% through the Unit-4 ramp; and (3) does Unit-4 reach 1.4× asset turn within three years of commissioning. Yes to all three justifies the current multiple; no to any one reprices the stock.

6. What I'd Tell a Young Analyst

Takeaway: Track the molecule book, not the quarter. The thesis lives or dies on commercial-molecule conversion and EBITDA-margin durability through Unit-4 capex.

What to watch every quarter:

• Commercial molecule count. FY26 added four; FY27-28 needs at least two-three each to justify multiple. This is the single most decision-useful disclosure.
• Phase-3 pipeline progression. Six today; any net adds or attrition reshape FY28-30 revenue base.
• EBITDA margin trajectory. 43.4% FY26, 48.1% Q4. Below 40% on a TTM basis is a yellow flag; below 35% is a red flag — implies pricing power or utilization is slipping.
• Unit-4 milestones. ₹1,200 Cr Phase 1, civil work in progress, peak capex hits March-27. Slips of more than two quarters compress the FY28-29 ramp.
• Customer-concentration disclosure. Management has acknowledged 5 of top 6 molecules go to three pharma majors; if a 10-K-style customer-concentration table ever appears, that is the chart that matters most.

What the market may be missing: backward integration on semaglutide gives Anthem the only Indian peptide-API position that competes with Chinese pricing — Q3 FY26 management said gross-margin upside from this is locked in. The microbial biosimilar contract (200L × 2 fermentation trains for a US customer) is a quiet new revenue line for FY28. Both are real options that don't show in trailing financials.

What would genuinely change the thesis: a single USFDA Form 483 with significant observations at Unit I or II (the existing approved plants), an unannounced loss of a top-three commercial molecule, or sustained EBITDA margin slippage below 38% over two consecutive quarters. The latter would imply the FFS-margin model has structurally weakened, not just blipped. Watch those three, and most of the noise is noise.